These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11698293)

  • 1. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.
    Bonifazi F; de Vivo A; Rosti G; Guilhot F; Guilhot J; Trabacchi E; Hehlmann R; Hochhaus A; Shepherd PC; Steegmann JL; Kluin-Nelemans HC; Thaler J; Simonsson B; Louwagie A; Reiffers J; Mahon FX; Montefusco E; Alimena G; Hasford J; Richards S; Saglio G; Testoni N; Martinelli G; Tura S; Baccarani M; ; ; ; ; ; ; ;
    Blood; 2001 Nov; 98(10):3074-81. PubMed ID: 11698293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
    Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
    Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
    Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
    Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alfa as primary treatment of chronic myeloid leukemia: long-term follow-up of 71 patients observed in a single center.
    Kloke O; Opalka B; Niederle N
    Leukemia; 2000 Mar; 14(3):389-92. PubMed ID: 10720131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
    Itoh T; Tamura S; Takemoto Y; Kakishita E
    Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
    Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M;
    J Clin Oncol; 2008 Jan; 26(1):106-11. PubMed ID: 18165644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term follow-Up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
    Blood; 1998 Sep; 92(5):1541-8. PubMed ID: 9716581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
    Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
    Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
    Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results.
    Alimena G; Meloni G; de Cuia MR; Rondinelli MB; Lo Coco F; Montefusco E; Mancini M; Pinto R; Nanni M; Cedrone M
    Leuk Lymphoma; 1993; 11 Suppl 1():281-91. PubMed ID: 7902746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
    Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
    Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
    Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at M. D. Anderson Cancer Center.
    Kantarjian HM; Talpaz M
    Leuk Lymphoma; 1993; 11 Suppl 1():169-74. PubMed ID: 8251891
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
    Hochhaus A; Reiter A; Saussele S; Reichert A; Emig M; Kaeda J; Schultheis B; Berger U; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Blood; 2000 Jan; 95(1):62-6. PubMed ID: 10607685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
    Nese M; de Bellis R; Urtiarte R; Di Landro J
    Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-alfa for chronic myeloid leukemia.
    Baccarani M; Russo D; Rosti G; Martinelli G
    Semin Hematol; 2003 Jan; 40(1):22-33. PubMed ID: 12563609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
    Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
    Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.